| 51 |
26480253 | [Anti-diabetics and chronic kidney disease]. | 2015 Sep-Oct |
1 |
| 52 |
26487791 | Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. | 2015 Oct |
1 |
| 53 |
23668534 | Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. | 2014 Feb |
1 |
| 54 |
24106875 | Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. | 2014 Mar |
1 |
| 55 |
24233023 | Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. | 2014 Feb |
1 |
| 56 |
24918793 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes. | 2014 May |
1 |
| 57 |
25089625 | Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. | 2014 |
2 |
| 58 |
25172519 | Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? | 2014 Oct |
2 |
| 59 |
25568561 | Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. | 2014 Oct |
1 |
| 60 |
22850868 | Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. | 2013 Mar |
4 |
| 61 |
23831441 | Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. | 2013 Sep |
1 |
| 62 |
23955995 | The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. | 2013 Nov |
1 |
| 63 |
23971789 | Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. | 2013 Dec |
1 |
| 64 |
24321717 | Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes. | 2013 Dec |
2 |
| 65 |
22432846 | GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. | 2012 Aug |
1 |
| 66 |
22982676 | Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. | 2012 Oct 12 |
1 |
| 67 |
21205107 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. | 2011 Mar |
1 |
| 68 |
21517658 | Liraglutide: a review of the first once-daily GLP-1 receptor agonist. | 2011 Mar |
1 |
| 69 |
21971158 | Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. | 2011 Dec |
5 |
| 70 |
20722676 | Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. | 2010 Sep |
1 |
| 71 |
20868233 | Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. | 2010 Dec |
1 |
| 72 |
19318378 | Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. | 2009 Jun |
1 |
| 73 |
19385979 | The scientific evidence: vildagliptin and the benefits of islet enhancement. | 2009 May |
2 |
| 74 |
19744424 | Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. | 2009 Sep |
1 |
| 75 |
17342635 | [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. | 2007 Mar 16 |
1 |
| 76 |
18217246 | Clinical management strategies for type 2 diabetes. | 2007 Dec |
1 |
| 77 |
16987706 | GLP-1 and type 2 diabetes: physiology and new clinical advances. | 2006 Dec |
1 |